GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Capex-to-Revenue

Nextage Therapeutics (XTAE:NXTG) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Nextage Therapeutics's Capital Expenditure for the six months ended in Dec. 2023 was ₪0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was ₪0.71 Mil.

Hence, Nextage Therapeutics's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.00.


Nextage Therapeutics Capex-to-Revenue Historical Data

The historical data trend for Nextage Therapeutics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Capex-to-Revenue Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial - 0.05 - - -

Nextage Therapeutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nextage Therapeutics's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nextage Therapeutics's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Capex-to-Revenue falls into.



Nextage Therapeutics Capex-to-Revenue Calculation

Nextage Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.876
=0.00

Nextage Therapeutics's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.713
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nextage Therapeutics  (XTAE:NXTG) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Nextage Therapeutics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nextage Therapeutics (XTAE:NXTG) Business Description

Traded in Other Exchanges
N/A
Address
Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines